Daily Stock List
Orgenesis, Inc. (ORGS)
Stock News Now, Streetwise Reports, Greenbackers, SmallCapNetwork, OTCPicks, and IRGnews Alert reported earlier on Orgenesis, Inc. (ORGS), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
OTCQB-listed, Orgenesis, Inc. is a fully-integrated cell therapy and contract development and manufacturing company. It has a novel therapeutic technology for the treatment of diabetes. In addition, the Company has a fully-owned subsidiary contract manufacturing and development company - MaSTherCell S.A. This subsidiary’s dedication is to cell therapy for advanced medicinal products. MaSTherCell specializes in the delivery of optimized process industrialization capacities to cell therapy organizations, Orgenesis is based in Germantown, Maryland.
Orgenesis has expertise and unique experience in cell therapy development and manufacturing. Additionally, by way of its Israeli subsidiary, Orgenesis Ltd., Orgenesis is a pioneer in the development of technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, Insulin Producing Cells (IPCs).
Orgenesis has a novel therapeutic approach in the treatment of diabetes through correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. The Company uses a molecular and cellular approach directed at transforming liver cells into functional insulin-producing cells as a treatment for diabetes. The new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.
The foundation of Orgenesis’ technology is on Intellectual Property (IP) licensed from Israel’s recognized Sheba Medical Center. The basis of the portfolio is on the pioneering work and two decades of research by the acclaimed researcher, Prof. Sarah Ferber.
Orgenesis has demonstrated promising results in in-vitro and in-vivo studies utilizing human liver tissues. The Company designed an efficient and clear work-plan to start clinical testing soon, allowing it to launch Phase I clinical trials following Food and Drug Administration (FDA) guidelines followed by the launch of Phase II clinical trials within a year.
Last week, Orgenesis announced that its wholly-owned subsidiary, MaSTherCell, signed a master service agreement with Servier for the development of a manufacturing platform for allogeneic cell therapies. With this master service agreement, MaSTherCell is developing a CAR-T cell therapy manufacturing platform that will enable industrial and commercial manufacturing of Servier's cell therapy products. This is a vital step in the development of these products for later stage clinical trials. Servier (based in France) is a global pharmaceutical company governed by a foundation.
Orgenesis, Inc. (ORGS), closed Friday's trading session at $0.50, up 11.11%, on 7,760 volume with 7 trades. The average volume for the last 60 days is 5,901 and the stock's 52-week low/high is $0.2352/$0.515.
RespireRx Pharmaceuticals, Inc. (RSPI)
We are reporting on RespireRx Pharmaceuticals, Inc. (RSPI) today, here at the QualityStocks Daily Newsletter.
Established in 1987, RespireRx Pharmaceuticals, Inc. is a leader in the development of medicines for respiratory disorders. These disorders include sleep apneas and drug-induced respiratory depression. The Company previously went by the name Cortex Pharmaceuticals, Inc. It changed its corporate name to RespireRx Pharmaceuticals, Inc. in December 2015. RespireRx Pharmaceuticals shares trade on the OTC Markets Group’s OTCQB, and the Company is headquartered in Glen Rock, New Jersey.
RespireRx Pharmaceuticals has filed over 400 patents in the United States and offshore that claim composition of matter, use, formulation, dosage, and mechanism of action. Use claims include treating sleep apnea and preventing or rescuing drug-induced respiratory depression, and also for improving memory and cognition, treating schizophrenia and other central nervous system indications.
The Company’s pharmaceutical candidates in development are derived from two platforms. One platform of medicines undergoing development by RespireRx is a class of proprietary compounds called ampakines. These act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptor sites in the brain. A number of ampakines, in oral and injectable form, are undergoing development by RespireRx Pharmaceuticals for the treatment of an array of breathing disorders.
The other platform is the class of compounds called cannabinoids. This includes, in particular, Dronabinol. Dronabinol (D9-THC, D9-tetrahydrocannabinol) is an oral capsule drug product. It is undergoing testing for clinical efficacy in patients with obstructive sleep apnea (OSA). Under a license agreement with the University of Illinois, RespireRx has rights to patents claiming the use of cannabinoids for the treatment of sleep-related breathing disorders.
Last month, RespireRx Pharmaceuticals announced positive results of the PACE (Pharmacotherapy of Apnea by Cannabimimetic Enhancement) trial conducted by Dr. David Carley and colleagues at the University of Illinois at Chicago and Northwestern University. The PACE trial is a Phase 2B study of dronabinol for the treatment of obstructive sleep apnea (OSA).
The Company states that the PACE trial clearly demonstrates that dronabinol considerably improves the primary outcome measures of Apnea Hypopnea Index (AHI), daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS) and overall patient satisfaction as measured by the Treatment Satisfaction Questionnaire for Medications (TSQM).
RespireRx Pharmaceuticals, Inc. (RSPI), closed Friday's trading session at $3.80, even for the day. The average volume for the last 60 days is 1,310 and the stock's 52-week low/high is $1.50/$12.35.
Eguana Technologies, Inc. (EGTYF)
InvestorsHub and Bloomberg reported on Eguana Technologies, Inc. (EGTYF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Eguana Technologies, Inc. designs and manufactures high performance power controls for commercial and residential energy storage systems. The Company is the foremost supplier of power controls for solar self-consumption, grid services, and demand charge applications at the grid edge. It has thousands of its proprietary energy storage inverters deployed in the European and North American markets. Eguana’s vision is to become the leading international supplier of intelligent power electronics for grid tied residential storage applications. Eguana Technologies has its corporate headquarters in Calgary, Alberta.
The Company delivers proven, durable, high quality solutions from its high capacity manufacturing facilities in Europe and North America. In addition, it delivers grid edge power electronics for fuel cell, photovoltaic, and battery applications.
Eguana’s Patented "pulsed step wave" technology takes a different approach to lessening conducted losses through sharing the current across parallel bridges and recombining into the AC output waveform through an inventive transformer topology and advanced control software. The single power conversion step further reduces losses. It also enables faster and more stable control loops than conventional inverters.
Eguana Technologies has its AC Battery™. The Eguana AC Battery is a complete grid ready power control solution. It accepts dispatch commands from any control network using open communication protocols. The AC Battery is built around the Company’s patented Bi-Direx power controls.
The AC Battery is 'control' ready. It can be commanded through a Sunspec-compliant ModBus interface employing any third-party energy management system. The AC Battery is a suitable fit for small commercial and light industrial applications. It is compatible with all advanced battery technologies. This is from Lithium-Ion over Lead-Acid to Redox Flow, Liquid Metal, or Sodium-Ion chemistries.
Last week, Eguana Technologies announced that it expanded its energy storage partnership with LG Chem. Development has started to optimize integration and delivery of LG Chem's new industry-leading JH3 battery cell technology for stationary storage systems as part of Eguana's AC Battery portfolio. Eguana will also expand its AC Battery product line to introduce a 15kVA/37kWh commercial energy storage product based on the JH3 cell in the same standalone module format in Q2 2017.
This week, Eguana Technologies and Bosch announced their collaboration on the Home Battery System (HBS) project. The Home Battery system and a summary of results to date will be on display at DistribuTECH in San Diego, California from January 31 - February 2, 2017 at ESCRYPT's booth #2351. Bosch is a leading worldwide supplier of technology and services.
Eguana Technologies, Inc. (EGTYF), closed Friday's trading session at $0.2265, down 11.52%, on 169,156 volume with 63 trades. The average volume for the last 60 days is 105,525 and the stock's 52-week low/high is $0.061/$0.325.
Medifirst Solutions, Inc. (MFST)
Daily Stock Motion, Growing Stocks Report, Michael Stone, Penny Pick Insider, Penny Stocks VIP, Research Driven Investor, SMS Penny Picks, Wall Street Beauties, WINNINGOTC, FatCat Stocks, Gryphon Digest, InvestorTrendz, Wall Street Mover, Value Penny Stocks, Hot Stock Profits, PennyStockScholar, PennyStocks24, OTCtipReporter, and Greenbackers reported previously on Medifirst Solutions, Inc. (MFST), and we report on the Company as well, here at the QualityStocks Daily Newsletter.
Medifirst Solutions, Inc. looks for pioneering medical and healthcare products and technologies targeted to medical and healthcare professionals and everyday consumers. The Company’s plan is to develop and establish a consumer and professional medical base and clientele to be used as a pipeline that will allow for expansion with new products and services. Medifirst Solutions is headquartered in Freehold, New Jersey. The Company lists on the OTC Markets’ OTCQB.
Medifirst Solutions’ commitment is to provide innovative drug free and pain free treatments, services, and also products for people to make better and healthier choices and improve their quality of life. Medifirst Solutions earlier acquired Florida-based Medical Lasers Manufacturer, Inc. This company has created a unique Laser Program designed for anti-aging applications. It will specialize in producing high quality diode-pumped solid-state lasers.
Medifirst Solutions, in response to its Premarket Notification 510(k) submission for "The Time Machine" Series Laser, received clearance from the U.S. Food and Drug Administration (FDA) to market its infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. The laser division will operate out of Medifirst Solutions’ wholly-owned subsidiary, Medical Lasers Manufacturer.
The intention of the Time Machine Series Lasers Model TTML-8102000 - 810/830nm is for use in temporary relief of minor muscle and joint pain, stiffness, minor arthritis pain, muscle spasm, temporary increase in local blood circulation, and temporary relaxation of muscles through topical elevated tissue temperature from infrared spectral emissions. The hand-held laser device, with precise accuracy, often gives patients instant results with no redness, swelling or down-time.
Last week, Medifirst Solutions updated shareholders concerning the Company’s earlier announcement regarding global sales for its FDA cleared Infrared Time Machine TTML-8102000 Laser Thermal Therapeutic Device. Medifirst said that its President and Medical Director will be presenting its FDA cleared laser technology at a medical conference today in Casablanca, Morocco, and on February 1, 2017 in Dubai, United Arab Emirates (UAE).
The conference in Casablanca is hosting approximately 100 physicians who will be specifically attending to view a presentation and demonstration of the Infrared Time Machine Laser. Medical Distributors in Morocco and Dubai have inquired about Medifirst Solutions’ time frame and capacity to produce and ship large bulk orders.
Medifirst Solutions, Inc. (MFST), closed Friday's trading session at $0.0084, up 9.09%, on 29,721,430 volume with 455 trades. The average volume for the last 60 days is 7,069,001 and the stock's 52-week low/high is $0.0025/$0.0243.
Cell MedX Corp. (CMXC)
The Observer, StockBlogs, SECFilings News, PennyStockLocks, ResearchOTC, and StockRockandRoll reported earlier on Cell MedX Corp. (CMXC), and we also report on the Company, here at the QualityStocks Daily Newsletter.
Cell MedX Corp concentrates on the discovery, development, and commercialization of therapeutic and non-therapeutic products, which promote general wellness and alleviate complications associated with medical conditions including, but not limited to, diabetes, Parkinson's disease, and high blood pressure. This is through developing technologies to help manage illness and related complications. The Company is at the forefront of creating devices that treat chronic and acute conditions for clinical and self-management care. An early development stage bio-technology company, Cell MedX is based in Carson City, Nevada.
Cell MedX manufactures and distributes medical devices powered by its proprietary, patented technology of low level current chiefly for supporting chemical (pharmaceutical) treatments for diabetes. The Company is making safe, results-oriented technologies combining electro-chemical applications and establishing new levels of treatment, called cellular medicine. Also, through its wholly-owned subsidiary, Avyonce Cosmedics, Inc., Cell MedX engages in the reselling and marketing of technology and equipment to the worldwide wellness industry and providing continuing education to health care professionals.
The Company’s aim is to release its initial lineup of commercial products. It will begin with its flagship product called ‘eBalance’, which works to improve the efficacy of the client’s existing medication regimes. The eBalance brand includes consumer product development and professional versions for use within medical facilities. The design of them are to address accelerated wound healing, abatement of diabetic neuropathies, improvement with glucose control, insulin resistance, and blood pressure.
The intention of eBalance technology is to expand the traditional healthcare model of diabetes management through enabling patients to manage their symptoms using a biosignal generating device that is user-friendly, causes no discomfort, and can easily be incorporated into any lifestyle. The eBalance technology will form the foundation for a product line that will be available to assist in the management of diabetes mellitus (T1DM and T2DM) and its complications, as a professional clinic-based and a home use device.
The eBalance Pro wellness device is an all-in-one, portable, and fully automated microcurrent delivery system. The device's software uses biofeedback algorithms to identify specific and personalized microcurrent frequencies to alleviate what are, in numerous cases, painful conditions. The basis of this device is on Cell MedX’s original eBalance Pro.
Earlier this month, Cell MedX announced that it received its first eBalance Pro wellness devices ready for commercial distribution. The design of these wellness devices is to promote general wellness and alleviate pain caused by chronic conditions, including sciatica, neuropathy, and arthritic pain.
This week, Cell MedX announced that it received an approval from Health Canada to begin its observational clinical trial in Canada. Cell MedX has engaged Nutrasource Diagnostics, Inc. (NDI) to launch the observational clinical trial of its unique and proprietary technology branded under the trade name eBalance.
The Trial’s intention is to assess the impact of eBalance therapy as an adjunct treatment on HbA1c after three months of therapy in relation to the subject's baseline data and medical history. Additional goals of the Trial will be to assess the effect of eBalance therapy on insulin resistance and sensitivity and on various complications caused by diabetes.
Cell MedX Corp. (CMXC), closed Friday's trading session at $0.35, up 9.31%, on 27,768 volume with 14 trades. The average volume for the last 60 days is 16,978 and the stock's 52-week low/high is $0.12/$0.4051.
Stealth Technologies Inc. (STTH)
The QualityStocks Daily Newsletter would like to spotlight Stealth Technologies Inc. (STTH). Today, Stealth Technologies Inc. closed trading at $0.04, up 33.33%, on 223,202 volume with 14 trades. The stock’s average daily volume over the past 60 days is 26,861, and its 52-week low/high is $0.015/$0.05.
Founded in 1999, Stealth Technologies Inc. (STTH) is focused on developing and marketing products that deliver cost effective, independently validated solutions for large addressable international and domestic markets. The company's primary target is identity protection and personal safety.
The Stealth Card represents the company's flagship solution for identity protection. Today there are more than 1.5 billion credit and debit cards in circulation with RFID chips, making it easier than ever for identity thieves to steal sensitive information without contact. The paper-thin Stealth Card offered by Stealth Technologies protects up to 12 RFID credit cards in a wallet without any batteries or charging requirements.
StealthIdentityTheft.com is an expansion of the company's commitment to provide first-rate identity protection solutions. The proprietary system underlying this identity protection and recovery service was designed in partnership with law enforcement officials. Utilizing the most effective methods of prevention involving a two-step process, StealthIdentityTheft.com is a superior answer to the non-stop identity theft taking place every day.
The international marketplace was infiltrated by Stealth Technologies when the company launched its 911 HELP NOW™ emergency medical alert device. Providing direct access with 911 service at a touch of a button, the device is packed with powerful features including a full year of battery life from standard AAA batteries, compact ergonomic design, 2-way voice and a durable, splash resistant design.
Stealth Mobile is the latest product offering introduced to leverage the Stealth Technologies' brand and sales channels established by the other products. Similar to the Stealth Card, Stealth Mobile prevents electronic pickpocketing. The product guards NFC transmissions emitted by cell phone devices, which can include personal information, messages and financial data.
Stealth Technologies recognizes the value of the rapid sales growth generated by these technologies and has multiple patents pending to safeguard its investments. With an expanding product suite and ongoing expansion into the identity theft protection marketplace, Stealth Technologies remains committed to its focus on increased growth and profitability. Disclaimer
Stealth Technologies Inc. Company Blog
Stealth Technologies Inc. News:
Stealth Technologies Announces 911 Help Now Generation II Product
Stealth Technologies Releases Record Sales Data
Stealth Technologies Reports Successful Product Launch to International Market
The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX). Today, ChineseInvestors.com closed trading at $2.24, up 10.89%, on 389,721 volume with 597 trades. The stock’s average daily volume over the past 60 days is 134,092 and its 52-week low/high is $0.12/$2.75.
Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.
Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.
At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.
CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.
The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.
Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world's first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer's disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.
In conjunction, CIIX's cannabis-focused "Yelp"-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide. Disclaimer
ChineseInvestors.com, Inc. (CIIX) Engages NetworkNewsWire for Corporate Communications Solutions
Covered in New Report from WallStreet Research™
ChineseInvestors.com Announces the Location of the new Headquarters for www.ChineseCBDoil.com, the World's First CBD Health Products Online Store in the Chinese Language
eXp World Holdings, Inc. (EXPI)
The QualityStocks Daily Newsletter would like to spotlight eXp World Holdings, Inc. (EXPI). Today, eXp World Holdings, Inc. closed trading at $3.45, up 0.58%, on 14,771 volume with 14 trades. The stock’s average daily volume over the past 60 days is 10,472, and its 52-week low/high is $0.697/$5.84.
eXp World Holdings, Inc. (EXPI) is the holding company for a number of businesses, most notably eXp Realty LLC, the Agent-Owned Cloud Brokerage™. eXp Realty is a full-service real estate brokerage offering 24/7 access to a suite of collaborative tools, training features and socialization channels designed to meet the unique needs of real estate brokers and agents. By creating a fully-immersive, cloud office environment for real estate professionals, eXp effectively reduces agents' overhead, increases their profits and provides greater service value to consumers.
Through eXp Realty's innovative platform, agents and brokers are afforded the opportunity to earn equity in exchange for production and contributions to company growth. Additionally, eXp features an aggressive revenue sharing program that pays agents a percentage of the gross commission income earned by fellow professionals they recruit into the company. The result is a shared ownership community featuring a synergistic and collaborative group of forward-thinking, entrepreneurial professionals. With the emergence of the internet as the most powerful property marketing and advertising medium, eXp's internet and cloud technologies have helped thousands of consumers find, buy or sell homes without the need for a brick and mortar real estate office.
Since its launch in October 2009, eXp Realty has experienced rapid growth, with brokerage service now offered in 35 U.S. states and Alberta, Canada. In February 2016, the company officially welcomed its 1,000th real estate professional into its family of agent-owners, up from just 467 agents at the end of 2014. Following this achievement, the Agent-Owned Cloud Brokerage claimed a spot among the top 50 real estate brokerages in the United States based on agent count, according to data from RISMEDIA's 2015 PowerBroker 500 Report.
Similarly, eXp Realty generated record financial results during 2015. Following the launch of two new initiatives – including an online lead generation program and a stock compensation plan – the company achieved a 71 percent year-over-year increase in net revenues, recording $22.87 million for the year. As it continues to expand its footprint across North America, eXp Realty will look to leverage its unique agent-owned business model to continue attracting driven, entrepreneurial agents and real estate industry leaders while promoting sustainable financial growth. Disclaimer
eXp World Holdings, Inc. Company Blog
eXp World Holdings, Inc. News:
eXp Realty Nearly Triples Agent Count in 2016
eXp World Holdings, Inc. Announces Appointment of Independent Director
eXp World Holdings, Inc. Retains MZ Group as its Investor Relations Advisor
Monaker Group, Inc. (MKGI)
The QualityStocks Daily Newsletter would like to spotlight Monaker Group, Inc. (MKGI). Today, Monaker Group, Inc. closed trading at $2.26, up 0.44%, on 10,630 volume with 8 trades. The stock’s average daily volume over the past 60 days is 8,608, and its 52-week low/high is $1.10/$4.89.
Monaker Group, Inc. (MKGI) is a technology driven travel company focused on leveraging resources to become a significant presence in the fastest growing sector of the $1.3 trillion travel and tourism market. The company's flagship brand, NextTrip.com, is the industry's first and only real-time booking engine that features alternative lodging (vacation home rentals, resort residences and unused timeshare inventory), as well as a full selection of airlines, hotels, cruises, rental cars, tours and concierge services. These features are combined into a single, easy-to-use platform that gives travelers complete real-time control when planning and booking their vacations.
NextTrip.com takes an integrated approach to the needs of travelers by combining multiple booking solutions into a highly intuitive real-time booking platform. Since its launch in February 2016, NextTrip has already grown to more than 250,000 units of vacation rental inventory. Monaker currently has roughly 1 million additional alternative lodging units under contract that will soon be added to the platform. This will place NextTrip among the top three largest vacation rental inventories and rival industry peers, Airbnb and HomeAway, in the rapidly expanding alternative lodging market. Unlike the competition, which book by request which can take hours or days before a lodging owner confirms, NextTrip's platform books in real-time, similar to online hotel bookings.
Most NextTrip listings are in desirable locations in the U.S., the EU and the Caribbean with about 20% exclusive listings. Monaker expects rapid exclusive listing growth because, unlike the competition, Monaker doesn't charge a sign-up fee, just a commission upon booking. The competition charges both. Monaker even has a proprietary solution to unlock Timeshare and Fractional Share properties as rental inventory.
Through strategic partnerships and acquisitions Monaker is now positioned to be a major player in the travel and alternative lodging sector. In addition Monaker is also the parent to Maupintour and Voyage TV.
In business for 65 years, Maupintour still leads the tour industry in the creation of outstanding, unique itineraries and has the highest repeat rate in the tour industry. Maupintour's upscale luxury services create a unique blend with the various product offerings of NextTrip. Voyage TV has thousands of hours of travel footage shot in over 30 countries worldwide. These 15,000 video clips of hotels, resorts, cruise, and destination activities are a treasure trove for vacation travel marketing.
With an established portfolio of travel brands, and a proven record acquiring, consolidating and integrating companies, Monaker is building a diverse and exciting foundation to drive the company's future. According to data from the U.S. Travel Association, direct spending on leisure travel by domestic and international travelers topped $650 billion in 2015. When combined with the fact that roughly 64 percent of travel companies are still considered small businesses, Monaker's all-inclusive approach to vacation booking through NextTrip and Maupintour strategically positions it for sustainable growth moving forward.
Monaker is headquartered in South Florida with offices in California. The company is led by a seasoned management team with decades of applicable industry experience. Monaker's Chairman and Chief Executive Officer Bill Kerby has over 18 years of experience in the media and travel industries, as well as 10 years of experience in the financial industry. Disclaimer
Monaker Group, Inc. Company Blog
Monaker Group, Inc. News:
Monaker Group Appoints Simon Orange to Board of Directors Appointment Advances Monaker's Plans for NASDAQ Listing
Monaker Group Shareholder Update -- 2016 Milestones and Transactional Business
Monaker Group (MKGI): Tip of the Travel Industry Iceberg -- SECFilings.com
GainClients, Inc. (GCLT)
The QualityStocks Daily Newsletter would like to spotlight GainClients, Inc. (GCLT). Today, GainClients, Inc. closed trading at $0.034, even for the day, on 56,800 volume with 10 trades. The stock’s average daily volume over the past 60 days is 130,968, and its 52-week low/high is $0.01/$0.20.
GainClients, Inc. (GCLT) is a software service company focused primarily on the development of marketing services for real estate professionals and valuable home search and area information tools for consumers. The company's innovations expound the popularity of online networks by helping real estate professionals better serve their clients through the sharing of accurate real estate data.
The company's main product is the GCard progressive networking system, which is designed to build and promote relationships among real estate professionals and their clients. Using the GCard, agents and brokers have the means to offer real estate, lending and title services information through an integrated, web-based network, capitalizing on the ongoing shift in consumer preference toward mobile solutions.
Similar to the features of other popular online networks, professional users can invite clients and their industry partners to join their GCard networks and be featured as trusted team members. From here, the teams can quickly provide real estate, lending and title services and information to consumers via smartphone and web. With better communication throughout the process of buying or selling homes, purchases can move more quickly and more comfortably to completion.
Strategic partnerships are an important component of GainClients' growth strategy. The company recently established a worldwide licensing arrangement with CLOVIS LLC, a partnership that will enable the distribution of both companies' proprietary technologies to the real estate industry. CLOVIS will use GainClients' GCard to develop a unique lead generation program for the broader real estate marketing and advertising industry.
GainClients also offers GCHomeSearch, its stand-alone website that provides non-real estate customers, such as lenders and title professionals, with accurate listing data, historical property data, neighborhood information and demographics. When used with the GCard, the user is also privy to loan payment calculators, loan rates, closing cost estimators and other tools needed to make intelligent buying and selling choices. Disclaimer
GainClients, Inc. Company Blog
GainClients, Inc. News:
GainClients, Inc. Retains Largest Real Estate Customer on its GCard Service
GainClients, Inc. Announces Corporate Update
GainClients, Inc. Enters Into A Licensing Agreement with Real Estate Technology Upstart CLOVIS, LLC To Expand Its Technology Platform
Today's Top 3
Fortune Stock Alerts
The QualityStocks Public Company Sponsor News